The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.
Posdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback